Intensive lifestyle intervention positively affects nonalcoholic fatty liver fibrosis score (NFS) and key metabolic parameters: A retrospective study
To date lifestyle intervention is the only proven therapy to treat nonalcoholic fatty liver disease (NAFLD). In this study, we retrospectively analyze the influence of a structured, multimodal 52-week lifestyle intervention program on NAFLD fibrosis score (NFS) as a marker for liver fibrosis. At bas...
Saved in:
Published in | Human nutrition & metabolism Vol. 35; p. 200247 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
01.03.2024
Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | To date lifestyle intervention is the only proven therapy to treat nonalcoholic fatty liver disease (NAFLD). In this study, we retrospectively analyze the influence of a structured, multimodal 52-week lifestyle intervention program on NAFLD fibrosis score (NFS) as a marker for liver fibrosis. At baseline, 16/47 subjects (34.0%) in our cohort displayed elevated NFS levels suggestive for advanced stages of liver fibrosis. Already after the initial 12-week hypocaloric fasting phase with a formula diet, this number decreased significantly and continued to decrease until the end of the program to 10/47 (21.3%). At baseline, 48.9% of the participants had impaired glucose metabolism, as defined by impaired fasting glucose, elevated HbA1c, or overt type 2 diabetes mellitus. This proportion reduced markedly to 31.9% by the end of the program. The proportion of advanced stages of liver fibrosis was especially high in the subgroup of participants with impaired glucose metabolism. This group particularly benefited from the lifestyle intervention program in terms of their NFS. The present study demonstrates that participants of structured multimodal lifestyle intervention programs with formula diets can significantly improve their metabolic parameters, such as body weight, fasting glucose, HbA1c, and lipids, and substantially reduce their risk of advanced liver fibrosis. Primary care providers must be aware of the close link between impaired glucose metabolism and increased liver-related risk and refer their metabolically ill patients to effective programs.
•Participants in weight loss programs may have advanced stages of liver fibrosis.•Lifestyle intervention programs may dramatically reduce body weight.•Advanced stages of liver fibrosis in the obese benefit from life style intervention. |
---|---|
AbstractList | To date lifestyle intervention is the only proven therapy to treat nonalcoholic fatty liver disease (NAFLD). In this study, we retrospectively analyze the influence of a structured, multimodal 52-week lifestyle intervention program on NAFLD fibrosis score (NFS) as a marker for liver fibrosis. At baseline, 16/47 subjects (34.0%) in our cohort displayed elevated NFS levels suggestive for advanced stages of liver fibrosis. Already after the initial 12-week hypocaloric fasting phase with a formula diet, this number decreased significantly and continued to decrease until the end of the program to 10/47 (21.3%). At baseline, 48.9% of the participants had impaired glucose metabolism, as defined by impaired fasting glucose, elevated HbA1c, or overt type 2 diabetes mellitus. This proportion reduced markedly to 31.9% by the end of the program. The proportion of advanced stages of liver fibrosis was especially high in the subgroup of participants with impaired glucose metabolism. This group particularly benefited from the lifestyle intervention program in terms of their NFS. The present study demonstrates that participants of structured multimodal lifestyle intervention programs with formula diets can significantly improve their metabolic parameters, such as body weight, fasting glucose, HbA1c, and lipids, and substantially reduce their risk of advanced liver fibrosis. Primary care providers must be aware of the close link between impaired glucose metabolism and increased liver-related risk and refer their metabolically ill patients to effective programs.
•Participants in weight loss programs may have advanced stages of liver fibrosis.•Lifestyle intervention programs may dramatically reduce body weight.•Advanced stages of liver fibrosis in the obese benefit from life style intervention. To date lifestyle intervention is the only proven therapy to treat nonalcoholic fatty liver disease (NAFLD). In this study, we retrospectively analyze the influence of a structured, multimodal 52-week lifestyle intervention program on NAFLD fibrosis score (NFS) as a marker for liver fibrosis. At baseline, 16/47 subjects (34.0%) in our cohort displayed elevated NFS levels suggestive for advanced stages of liver fibrosis. Already after the initial 12-week hypocaloric fasting phase with a formula diet, this number decreased significantly and continued to decrease until the end of the program to 10/47 (21.3%). At baseline, 48.9% of the participants had impaired glucose metabolism, as defined by impaired fasting glucose, elevated HbA1c, or overt type 2 diabetes mellitus. This proportion reduced markedly to 31.9% by the end of the program. The proportion of advanced stages of liver fibrosis was especially high in the subgroup of participants with impaired glucose metabolism. This group particularly benefited from the lifestyle intervention program in terms of their NFS. The present study demonstrates that participants of structured multimodal lifestyle intervention programs with formula diets can significantly improve their metabolic parameters, such as body weight, fasting glucose, HbA1c, and lipids, and substantially reduce their risk of advanced liver fibrosis. Primary care providers must be aware of the close link between impaired glucose metabolism and increased liver-related risk and refer their metabolically ill patients to effective programs. AbstractTo date lifestyle intervention is the only proven therapy to treat nonalcoholic fatty liver disease (NAFLD). In this study, we retrospectively analyze the influence of a structured, multimodal 52-week lifestyle intervention program on NAFLD fibrosis score (NFS) as a marker for liver fibrosis. At baseline, 16/47 subjects (34.0%) in our cohort displayed elevated NFS levels suggestive for advanced stages of liver fibrosis. Already after the initial 12-week hypocaloric fasting phase with a formula diet, this number decreased significantly and continued to decrease until the end of the program to 10/47 (21.3%). At baseline, 48.9% of the participants had impaired glucose metabolism, as defined by impaired fasting glucose, elevated HbA1c, or overt type 2 diabetes mellitus. This proportion reduced markedly to 31.9% by the end of the program. The proportion of advanced stages of liver fibrosis was especially high in the subgroup of participants with impaired glucose metabolism. This group particularly benefited from the lifestyle intervention program in terms of their NFS. The present study demonstrates that participants of structured multimodal lifestyle intervention programs with formula diets can significantly improve their metabolic parameters, such as body weight, fasting glucose, HbA1c, and lipids, and substantially reduce their risk of advanced liver fibrosis. Primary care providers must be aware of the close link between impaired glucose metabolism and increased liver-related risk and refer their metabolically ill patients to effective programs. |
ArticleNumber | 200247 |
Author | Gummlich, Benjamin Peter Michael Gollisch, Katja Susanne Claudia Raddatz, Dirk |
Author_xml | – sequence: 1 givenname: Benjamin Peter Michael surname: Gummlich fullname: Gummlich, Benjamin Peter Michael email: b.gummlich@gmail.com – sequence: 2 givenname: Dirk orcidid: 0000-0002-9509-4462 surname: Raddatz fullname: Raddatz, Dirk email: draddatz@med.uni-goettingen.de – sequence: 3 givenname: Katja Susanne Claudia orcidid: 0000-0001-8266-6516 surname: Gollisch fullname: Gollisch, Katja Susanne Claudia email: katja.gollisch@med.uni-goettingen.de |
BookMark | eNqFUk1v1DAQjVCRKKU_gJuPcNjF9jpOAhJSVVFYqYJD4WxNnDF1yNor210pP4T_y6SLqgoJuIzt8bw3H2-eVychBqyql4KvBRf6zbi-Dbu15FKRIds8qU6l1nolVNecPLo_q85zHjnFtILzuj6tfm5DwZD9AdnkHeYyT8g8-dIBQ_ExsH3MvtD_NDNwDm3JjNLDZONtnLxlDkqZCXzAxJzvE4Vnlm1MyF59vrp5zSAM7AfObIcF-nvIHhLQC1N-yy5YwkKgPTEvVeRyN8wvqqcOpoznv8-z6tvVh6-Xn1bXXz5uLy-uV1bpTVk1SqJGx22HoDvEurMNuBabthUKOPR26ABdp7kbBjtwDeRv-tpC3zagms1ZtT3yDhFGs09-B2k2Eby5d8T03UAq3k5owNZ13TtshHVKbUQnleWtcE4O0nItiUscuSx1kxO6Bz7BzSKTGQ3JZBaZzFEmwrw7YpCaPHhMJluPweLgE82DqvD_RL__A20nH7yFicaNeYx3iXTKRpgsDTc3yxosWyAVbQDvFBF0fyf4T_Jfxe_I8Q |
Cites_doi | 10.1053/j.gastro.2015.04.005 10.1001/jama.2020.2298 10.1016/j.metabol.2018.09.005 10.3390/nu10081022 10.1016/j.dsx.2008.04.012 10.1002/hep.23276 10.1159/000355822 10.1038/nrendo.2017.80 10.4103/2230-8210.163172 10.1002/hep.21496 10.1016/j.tips.2017.04.004 10.1038/ijo.2011.107 10.3390/jcm10245755 10.1159/000282080 10.1146/annurev-pathol-012615-044224 10.1002/hep.25539 10.1007/s42000-018-0021-9 10.1002/hep4.1572 10.1007/s10620-014-3380-3 |
ContentType | Journal Article |
Copyright | 2024 The Authors The Authors |
Copyright_xml | – notice: 2024 The Authors – notice: The Authors |
DBID | 6I. AAFTH AAYXX CITATION DOA |
DOI | 10.1016/j.hnm.2024.200247 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef |
DatabaseTitleList | |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Diet & Clinical Nutrition |
EISSN | 2666-1497 |
EndPage | 200247 |
ExternalDocumentID | oai_doaj_org_article_ac555bfe71cf4431924c081ff2d2c062 10_1016_j_hnm_2024_200247 S2666149724000094 1_s2_0_S2666149724000094 |
GroupedDBID | .1- .FO 0R~ 1P~ AAEDW AAFWJ AAHBH AALRI AAXUO AAYWO ACVFH ADCNI ADVLN AEUPX AEXQZ AFJKZ AFPKN AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M~E OK1 ROL Z5R AAHOK AFCTW 6I. AAFTH AAYXX CITATION |
ID | FETCH-LOGICAL-c463t-742e6ef0c9ea69ee59c7af8e78814a0abcd9aef960fddcd06a8147b5cab87a473 |
IEDL.DBID | DOA |
ISSN | 2666-1497 |
IngestDate | Wed Aug 27 01:30:14 EDT 2025 Tue Jul 01 01:18:30 EDT 2025 Sat Feb 17 16:07:48 EST 2024 Tue Feb 25 20:01:05 EST 2025 Tue Aug 26 17:47:15 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Obesity NAFLD liver fibrosis Diabetes mellitus Opitfast 52 Weight lifestyle intervention BMI |
Language | English |
License | This is an open access article under the CC BY-NC-ND license. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c463t-742e6ef0c9ea69ee59c7af8e78814a0abcd9aef960fddcd06a8147b5cab87a473 |
ORCID | 0000-0002-9509-4462 0000-0001-8266-6516 |
OpenAccessLink | https://doaj.org/article/ac555bfe71cf4431924c081ff2d2c062 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_ac555bfe71cf4431924c081ff2d2c062 crossref_primary_10_1016_j_hnm_2024_200247 elsevier_sciencedirect_doi_10_1016_j_hnm_2024_200247 elsevier_clinicalkeyesjournals_1_s2_0_S2666149724000094 elsevier_clinicalkey_doi_10_1016_j_hnm_2024_200247 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-03-01 |
PublicationDateYYYYMMDD | 2024-03-01 |
PublicationDate_xml | – month: 03 year: 2024 text: 2024-03-01 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Human nutrition & metabolism |
PublicationYear | 2024 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
References | Bellentani, Scaglioni, Marino, Bedogni (bib2) 2010; 28 Hardy, Oakley, Anstee, Day (bib3) 2016; 11 Winkler (bib7) 2013; 6 Bischoff (bib14) Apr. 2012; 36 Sanyal, Mukherjee, Raychaudhuri, Ghosh, Mukherjee, Chowdhury (bib21) 2015; 19 Dobbie, Kassab, Davison, Grace, Cuthbertson, Hydes (bib25) Jan. 2021; 10 Perera, Lohsoonthorn, Jiamjarasrangsi, Lertmaharit, Williams (bib20) Sep. 2008; 2 Sheka, Adeyi, Thompson, Hameed, Crawford, Ikramuddin (bib4) Mar. 2020; 323 Vilar-Gomez (bib8) Aug. 2015; 149 Angulo (bib15) Apr. 2007; 45 Lomonaco (bib23) May 2012; 55 Promrat (bib6) Jan. 2010; 51 Hauner (bib13) 2014; 8 Chooi, Ding, Magkos (bib1) Mar. 2019; 92 Glass (bib9) Apr. 2015; 60 Iogna Prat, Tsochatzis (bib17) Jun. 2018; 17 Petersen, Vatner, Shulman (bib22) Oct. 2017; 13 Kempf, Röhling, Niedermeier, Gärtner, Martin (bib18) Aug. 2018; 10 Arnouk, Rachakonda, Jaiyeola, Behari (bib12) 2020; 4 (bib16) Dec. 2021; 45 Petersen, Shulman (bib24) 2017; 38 Correia (bib19) May 2022 Lomonaco (10.1016/j.hnm.2024.200247_bib23) 2012; 55 Correia (10.1016/j.hnm.2024.200247_bib19) 2022 Winkler (10.1016/j.hnm.2024.200247_bib7) 2013; 6 Hauner (10.1016/j.hnm.2024.200247_bib13) 2014; 8 Sanyal (10.1016/j.hnm.2024.200247_bib21) 2015; 19 Hardy (10.1016/j.hnm.2024.200247_bib3) 2016; 11 Arnouk (10.1016/j.hnm.2024.200247_bib12) 2020; 4 Chooi (10.1016/j.hnm.2024.200247_bib1) 2019; 92 Sheka (10.1016/j.hnm.2024.200247_bib4) 2020; 323 Glass (10.1016/j.hnm.2024.200247_bib9) 2015; 60 Petersen (10.1016/j.hnm.2024.200247_bib22) 2017; 13 Promrat (10.1016/j.hnm.2024.200247_bib6) 2010; 51 Bellentani (10.1016/j.hnm.2024.200247_bib2) 2010; 28 Kempf (10.1016/j.hnm.2024.200247_bib18) 2018; 10 Dobbie (10.1016/j.hnm.2024.200247_bib25) 2021; 10 Petersen (10.1016/j.hnm.2024.200247_bib24) 2017; 38 (10.1016/j.hnm.2024.200247_bib16) 2021; 45 Vilar-Gomez (10.1016/j.hnm.2024.200247_bib8) 2015; 149 Bischoff (10.1016/j.hnm.2024.200247_bib14) 2012; 36 Iogna Prat (10.1016/j.hnm.2024.200247_bib17) 2018; 17 Angulo (10.1016/j.hnm.2024.200247_bib15) 2007; 45 Perera (10.1016/j.hnm.2024.200247_bib20) 2008; 2 |
References_xml | – volume: 4 start-page: 1419 year: 2020 end-page: 1429 ident: bib12 article-title: Differential outcomes and clinical challenges of NAFLD with extreme obesity publication-title: Hepatology Communications – volume: 2 start-page: 171 year: Sep. 2008 end-page: 178 ident: bib20 article-title: Association between elevated liver enzymes and metabolic syndrome among Thai adults publication-title: Diabetes Metabol. Syndr. – volume: 60 start-page: 1024 year: Apr. 2015 end-page: 1030 ident: bib9 article-title: Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis publication-title: Dig. Dis. Sci. – volume: 149 start-page: 367 year: Aug. 2015 end-page: 378.e5 ident: bib8 article-title: Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis publication-title: Gastroenterology – volume: 17 start-page: 219 year: Jun. 2018 end-page: 229 ident: bib17 article-title: The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD) publication-title: Hormones (Basel) – volume: 45 start-page: S17 year: Dec. 2021 end-page: S38 ident: bib16 article-title: 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022 publication-title: Diabetes Care – volume: 36 start-page: 614 year: Apr. 2012 end-page: 624 ident: bib14 article-title: Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life--a prospective study publication-title: Int. J. Obes. – volume: 51 start-page: 121 year: Jan. 2010 end-page: 129 ident: bib6 article-title: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis (NASH) publication-title: Hepatology – volume: 55 start-page: 1389 year: May 2012 end-page: 1397 ident: bib23 article-title: Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease publication-title: Hepatology – volume: 19 start-page: 597 year: 2015 end-page: 601 ident: bib21 article-title: Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes publication-title: Indian J Endocrinol Metab – volume: 13 start-page: 572 year: Oct. 2017 end-page: 587 ident: bib22 article-title: Regulation of hepatic glucose metabolism in health and disease publication-title: Nat. Rev. Endocrinol. – volume: 28 start-page: 155 year: 2010 end-page: 161 ident: bib2 article-title: Epidemiology of non-alcoholic fatty liver disease publication-title: Dig. Dis. – volume: 10 year: Jan. 2021 ident: bib25 article-title: Low screening rates despite a high prevalence of significant liver fibrosis in people with diabetes from primary and secondary care publication-title: J. Clin. Med. – volume: 11 start-page: 451 year: 2016 end-page: 496 ident: bib3 article-title: Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum publication-title: Annu. Rev. Pathol. – volume: 10 start-page: E1022 year: Aug. 2018 ident: bib18 article-title: Individualized meal replacement therapy improves clinically relevant long-term glycemic control in poorly controlled type 2 diabetes patients publication-title: Nutrients – volume: 92 start-page: 6 year: Mar. 2019 end-page: 10 ident: bib1 article-title: The epidemiology of obesity publication-title: Metabolism – volume: 8 start-page: 179 year: 2014 end-page: 221 ident: bib13 article-title: “Interdisziplinäre Leitlinie der Qualität S3 zur „Prävention und Therapie der Adipositas”: der Deutschen Adipositas-Gesellschaft e.V.; der Deutschen Diabetes Gesellschaft; der Deutschen Gesellschaft für Ernährung e.V.; der Deutschen Gesellschaft für Ernährungsmedizin e.V. Version 2.0 (April 2014); AWMF-Register Nr. 050-001,” publication-title: Adipositas – volume: 323 start-page: 1175 year: Mar. 2020 end-page: 1183 ident: bib4 article-title: Nonalcoholic steatohepatitis: a review publication-title: JAMA – volume: 45 start-page: 846 year: Apr. 2007 end-page: 854 ident: bib15 article-title: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD publication-title: Hepatology – volume: 6 start-page: 469 year: 2013 end-page: 480 ident: bib7 article-title: Effectiveness of a low-calorie weight loss program in moderately and severely obese patients publication-title: Obes. Facts – year: May 2022 ident: bib19 article-title: “Effect of Very Low-Calorie Diet on the Reduction of Liver Steatosis and Fibrosis in Subjects with Obesity and Non-alcoholic Fatty Liver Disease,” clinicaltrials.Gov, Clinical Trial Registration NCT04861571 – volume: 38 start-page: 649 year: 2017 end-page: 665 ident: bib24 article-title: Roles of diacylglycerols and ceramides in hepatic insulin resistance publication-title: Trends Pharmacol. Sci. – volume: 45 start-page: S17 issue: Supplement_1 year: 2021 ident: 10.1016/j.hnm.2024.200247_bib16 article-title: 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022 publication-title: Diabetes Care – volume: 149 start-page: 367 issue: 2 year: 2015 ident: 10.1016/j.hnm.2024.200247_bib8 article-title: Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis publication-title: Gastroenterology doi: 10.1053/j.gastro.2015.04.005 – volume: 323 start-page: 1175 issue: 12 year: 2020 ident: 10.1016/j.hnm.2024.200247_bib4 article-title: Nonalcoholic steatohepatitis: a review publication-title: JAMA doi: 10.1001/jama.2020.2298 – volume: 92 start-page: 6 year: 2019 ident: 10.1016/j.hnm.2024.200247_bib1 article-title: The epidemiology of obesity publication-title: Metabolism doi: 10.1016/j.metabol.2018.09.005 – volume: 10 start-page: E1022 issue: 8 year: 2018 ident: 10.1016/j.hnm.2024.200247_bib18 article-title: Individualized meal replacement therapy improves clinically relevant long-term glycemic control in poorly controlled type 2 diabetes patients publication-title: Nutrients doi: 10.3390/nu10081022 – volume: 2 start-page: 171 issue: 3 year: 2008 ident: 10.1016/j.hnm.2024.200247_bib20 article-title: Association between elevated liver enzymes and metabolic syndrome among Thai adults publication-title: Diabetes Metabol. Syndr. doi: 10.1016/j.dsx.2008.04.012 – volume: 51 start-page: 121 issue: 1 year: 2010 ident: 10.1016/j.hnm.2024.200247_bib6 article-title: Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis (NASH) publication-title: Hepatology doi: 10.1002/hep.23276 – volume: 6 start-page: 469 issue: 5 year: 2013 ident: 10.1016/j.hnm.2024.200247_bib7 article-title: Effectiveness of a low-calorie weight loss program in moderately and severely obese patients publication-title: Obes. Facts doi: 10.1159/000355822 – volume: 13 start-page: 572 issue: 10 year: 2017 ident: 10.1016/j.hnm.2024.200247_bib22 article-title: Regulation of hepatic glucose metabolism in health and disease publication-title: Nat. Rev. Endocrinol. doi: 10.1038/nrendo.2017.80 – volume: 19 start-page: 597 issue: 5 year: 2015 ident: 10.1016/j.hnm.2024.200247_bib21 article-title: Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes publication-title: Indian J Endocrinol Metab doi: 10.4103/2230-8210.163172 – volume: 45 start-page: 846 issue: 4 year: 2007 ident: 10.1016/j.hnm.2024.200247_bib15 article-title: The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD publication-title: Hepatology doi: 10.1002/hep.21496 – volume: 38 start-page: 649 issue: 7 year: 2017 ident: 10.1016/j.hnm.2024.200247_bib24 article-title: Roles of diacylglycerols and ceramides in hepatic insulin resistance publication-title: Trends Pharmacol. Sci. doi: 10.1016/j.tips.2017.04.004 – volume: 36 start-page: 614 issue: 4 year: 2012 ident: 10.1016/j.hnm.2024.200247_bib14 article-title: Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life--a prospective study publication-title: Int. J. Obes. doi: 10.1038/ijo.2011.107 – volume: 10 issue: 24 year: 2021 ident: 10.1016/j.hnm.2024.200247_bib25 article-title: Low screening rates despite a high prevalence of significant liver fibrosis in people with diabetes from primary and secondary care publication-title: J. Clin. Med. doi: 10.3390/jcm10245755 – volume: 28 start-page: 155 issue: 1 year: 2010 ident: 10.1016/j.hnm.2024.200247_bib2 article-title: Epidemiology of non-alcoholic fatty liver disease publication-title: Dig. Dis. doi: 10.1159/000282080 – volume: 11 start-page: 451 year: 2016 ident: 10.1016/j.hnm.2024.200247_bib3 article-title: Nonalcoholic fatty liver disease: Pathogenesis and disease spectrum publication-title: Annu. Rev. Pathol. doi: 10.1146/annurev-pathol-012615-044224 – volume: 55 start-page: 1389 issue: 5 year: 2012 ident: 10.1016/j.hnm.2024.200247_bib23 article-title: Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease publication-title: Hepatology doi: 10.1002/hep.25539 – volume: 8 start-page: 179 issue: 4 year: 2014 ident: 10.1016/j.hnm.2024.200247_bib13 publication-title: Adipositas – volume: 17 start-page: 219 issue: 2 year: 2018 ident: 10.1016/j.hnm.2024.200247_bib17 article-title: The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD) publication-title: Hormones (Basel) doi: 10.1007/s42000-018-0021-9 – volume: 4 start-page: 1419 issue: 10 year: 2020 ident: 10.1016/j.hnm.2024.200247_bib12 article-title: Differential outcomes and clinical challenges of NAFLD with extreme obesity publication-title: Hepatology Communications doi: 10.1002/hep4.1572 – volume: 60 start-page: 1024 issue: 4 year: 2015 ident: 10.1016/j.hnm.2024.200247_bib9 article-title: Total body weight loss of ≥ 10 % is associated with improved hepatic fibrosis in patients with nonalcoholic steatohepatitis publication-title: Dig. Dis. Sci. doi: 10.1007/s10620-014-3380-3 – year: 2022 ident: 10.1016/j.hnm.2024.200247_bib19 |
SSID | ssj0002810055 |
Score | 2.2490914 |
Snippet | To date lifestyle intervention is the only proven therapy to treat nonalcoholic fatty liver disease (NAFLD). In this study, we retrospectively analyze the... AbstractTo date lifestyle intervention is the only proven therapy to treat nonalcoholic fatty liver disease (NAFLD). In this study, we retrospectively analyze... |
SourceID | doaj crossref elsevier |
SourceType | Open Website Index Database Publisher |
StartPage | 200247 |
SubjectTerms | BMI Diabetes mellitus Gastroenterology and Hepatology lifestyle intervention liver fibrosis NAFLD Obesity Opitfast 52 Weight |
Title | Intensive lifestyle intervention positively affects nonalcoholic fatty liver fibrosis score (NFS) and key metabolic parameters: A retrospective study |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666149724000094 https://www.clinicalkey.es/playcontent/1-s2.0-S2666149724000094 https://dx.doi.org/10.1016/j.hnm.2024.200247 https://doaj.org/article/ac555bfe71cf4431924c081ff2d2c062 |
Volume | 35 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQT1wQFBDhUc2hQoAUkbh-JL0V2lWF1L2USr1Zjj0WqbYL2gSkvfRf8H8Zx8kqB1QuXHKw_Ipn7JmxP39m7LC2StUSfR5sY3OhnMwr1DxH3siGIhIsinjf-WKpzq_El2t5PXvqK2LCEj1wGriP1kkpm4C6dEGQtaN4wZEZC4F77oq0-pLNmwVTN8OWURnZpaZjzAHQ9W0db57zYSOFx-dUZoZo4Ouf2aOZjVk8Zo9G5xBOUqeesAe43mfZaYs9vIWRwXMFy4lA_yn7vUOgw6oNtMBvVwjtDMYICZT1C1dbsAm6AevofA8P47YOgu37LRUmjYZAoTNl76CL3Jbwbrm4fA927YEmOtxiT_oSi0S28NuIoumO4QQ22G--T_c1YWCrfcauFmdfP5_n40MLuRPqqM8pPEaFoXA1WlUjytppG0hmVVUKW9jG-dpioGAneO98oSyl60Y621TaCn30nO1R3_EFg5pr6a2gqK1EEY90vHJUN9euCkrYkLEP06ibH4lPw0xAsxtDIjJRRCaJKGOfolx2GSMV9pBACmJGBTH_UpCM8UmqZrptSsNGFbX3taz_Vgi7cYZ3pjQdN4W5JAeHPJxaRyxuhGlmTOxKjk5Mck7ub_Dl__jVV-xhrDJB5F6zvX7zE9-Qz9Q3B8P0oO_F3dkf-hkZjQ |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intensive+lifestyle+intervention+positively+affects+nonalcoholic+fatty+liver+fibrosis+score+%28NFS%29+and+key+metabolic+parameters%3A+A+retrospective+study&rft.jtitle=Human+nutrition+%26+metabolism&rft.au=Gummlich%2C+Benjamin+Peter+Michael&rft.au=Raddatz%2C+Dirk&rft.au=Gollisch%2C+Katja+Susanne+Claudia&rft.date=2024-03-01&rft.issn=2666-1497&rft.eissn=2666-1497&rft.volume=35&rft.spage=200247&rft_id=info:doi/10.1016%2Fj.hnm.2024.200247&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_hnm_2024_200247 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26661497%2FS2666149723X00048%2Fcov150h.gif |